Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.
Peter Angus, Rhys Vaughan, Shelly Xiong, Huiling Yang, William Delaney, Craig Gibbs, Carol Brosgart, Danielle Colledge, Rosalind Edwards, Anna Ayres, Angeline Bartholomeusz, Stephen Locarnini
Gastroenterology | Published : 2003
BACKGROUND & AIMS: Adefovir dipivoxil effectively inhibits both hepatitis B virus (HBV) replication and disease activity in patients with chronic hepatitis B. Resistance to treatment was not observed in 2 recent large placebo-controlled 48-week studies with this drug. The aim of this study was to characterize adefovir resistance in a patient who developed clinical and virologic evidence of breakthrough during a 96-week course of treatment. METHODS: HBV DNA was PCR amplified and sequenced. Phenotypic studies used patient-derived HBV as well as specific mutations created by site-directed mutagenesis of a HBV/baculovirus recombinant. RESULTS: Following the commencement of treatment with adefovi..View full abstract